Atria Investments LLC cut its position in Genmab A/S (NASDAQ:GMAB – Get Rating) by 16.0% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 30,346 shares of the company’s stock after selling 5,765 shares during the quarter. Atria Investments LLC’s holdings in Genmab A/S were worth $1,098,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors also recently made changes to their positions in the company. DAVENPORT & Co LLC raised its position in shares of Genmab A/S by 2.1% in the 4th quarter. DAVENPORT & Co LLC now owns 15,439 shares of the company’s stock valued at $611,000 after buying an additional 322 shares in the last quarter. Wetherby Asset Management Inc. grew its holdings in shares of Genmab A/S by 2.6% during the 4th quarter. Wetherby Asset Management Inc. now owns 14,389 shares of the company’s stock valued at $569,000 after purchasing an additional 358 shares during the last quarter. Bessemer Group Inc. grew its holdings in shares of Genmab A/S by 50.3% during the 4th quarter. Bessemer Group Inc. now owns 1,156 shares of the company’s stock valued at $46,000 after purchasing an additional 387 shares during the last quarter. Cim LLC grew its holdings in shares of Genmab A/S by 1.7% during the 1st quarter. Cim LLC now owns 27,994 shares of the company’s stock valued at $1,002,000 after purchasing an additional 465 shares during the last quarter. Finally, SG Americas Securities LLC grew its holdings in shares of Genmab A/S by 9.3% during the 1st quarter. SG Americas Securities LLC now owns 6,050 shares of the company’s stock valued at $219,000 after purchasing an additional 513 shares during the last quarter. 5.92% of the stock is currently owned by institutional investors and hedge funds.
Genmab A/S Stock Performance
Shares of NASDAQ GMAB opened at $36.47 on Thursday. Genmab A/S has a 52-week low of $26.19 and a 52-week high of $49.07. The company’s 50 day moving average price is $31.78 and its 200-day moving average price is $33.36. The company has a market capitalization of $23.98 billion, a P/E ratio of 63.98, a price-to-earnings-growth ratio of 1.52 and a beta of 0.86.
Genmab A/S (NASDAQ:GMAB – Get Rating) last released its earnings results on Wednesday, May 11th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. Genmab A/S had a net margin of 26.34% and a return on equity of 10.90%. The company had revenue of $319.54 million for the quarter, compared to the consensus estimate of $304.16 million. Analysts forecast that Genmab A/S will post 0.88 earnings per share for the current year.
Analyst Upgrades and Downgrades
GMAB has been the topic of several research reports. Cowen initiated coverage on shares of Genmab A/S in a report on Monday, May 2nd. They set a “market perform” rating and a $38.00 price target on the stock. Morgan Stanley decreased their price target on shares of Genmab A/S to $29.00 and set an “underweight” rating on the stock in a report on Tuesday, May 17th. HC Wainwright boosted their target price on shares of Genmab A/S from $47.00 to $49.00 and gave the stock a “buy” rating in a report on Wednesday, July 20th. Cowen started coverage on shares of Genmab A/S in a report on Monday, May 2nd. They set a “market perform” rating on the stock. Finally, TheStreet lowered shares of Genmab A/S from a “b-” rating to a “c+” rating in a report on Monday, June 13th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and five have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $424.09.
Genmab A/S Company Profile
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.
Receive News & Ratings for Genmab A/S Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Genmab A/S and related companies with MarketBeat.com’s FREE daily email newsletter.